TME Pharma NV (FRA:0N6A) Total Liabilities : €1.79 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is TME Pharma NV Total Liabilities?

TME Pharma NV's Total Liabilities for the quarter that ended in Dec. 2024 was €1.79 Mil.

TME Pharma NV's quarterly Total Liabilities declined from Dec. 2023 (€2.79 Mil) to Jun. 2024 (€1.38 Mil) but then increased from Jun. 2024 (€1.38 Mil) to Dec. 2024 (€1.79 Mil).

TME Pharma NV's annual Total Liabilities declined from Dec. 2022 (€6.51 Mil) to Dec. 2023 (€2.79 Mil) and declined from Dec. 2023 (€2.79 Mil) to Dec. 2024 (€1.79 Mil).

TME Pharma NV Total Liabilities Historical Data

The historical data trend for TME Pharma NV's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV Total Liabilities Chart

TME Pharma NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

2.96

5.27

6.51

2.79

1.79

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial															6.51	3.63	2.79	1.38	1.79

TME Pharma NV Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

TME Pharma NV's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.792	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.79

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	3.406	-	1.614
	=	1.79

TME Pharma NV's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1.792	+	(0	+	0
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1.79

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	3.406	-	1.614
	=	1.79

TME Pharma NV Total Liabilities Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (FRA:0N6A) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

ALTME:France

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product is NOX-A12 which is being developed in solid tumors. In the Phase 1/2 trial in chemotherapy-resistant 1st line glioblastoma (brain cancer) patients, NOX-12 + radiotherapy + anti-VEGF has shown a statistically survival benefit over both standard of care reference cohort (p=0.003, HR: 0.30) and as well as vs. patients receiving NOX-A12 and radiotherapy alone (p=0.021, HR: 0.34).

TME Pharma NV Headlines

No Headlines